A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.

doi:10.1016/j.jhep.2014.07.022

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.

Journal of hepatology - 1 Dec 2014

Muir Andrew J, Arora Sanjeev, Everson Gregory, Flisiak Robert, George Jacob, Ghalib Reem, Gordon Stuart C, Gray Todd, Greenbloom Susan, Hassanein Tarek, Hillson Jan, Horga Maria Arantxa, Jacobson Ira M, Jeffers Lennox, Kowdley Kris V, Lawitz Eric, Lueth Stefan, Rodriguez-Torres Maribel, Rustgi Vinod, Shemanski Lynn, Shiffman Mitchell L, Srinivasan Subasree, Vargas Hugo E, Vierling John M, Xu Dong, Lopez-Talavera Juan C, Zeuzem Stefan

Abstract excerpt

BACKGROUND & AIMS: Peginterferon lambda-1a (Lambda) is a type-III interferon with similar antiviral activity to alfa interferons but with a diminished extrahepatic receptor distribution, reducing the risk for extrahepatic adverse events. METHODS: This was a randomized, blinded, actively-controlled, multicentre phase 2b dose-ranging study in patients chronically infected with HCV genotypes 1-4. Treatment-naive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed

Identifiers

PMID: 25064437
DOI: 10.1016/j.jhep.2014.07.022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.PMID 25064437Read ↗

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.Semantic proximity Read ↗

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.Semantic proximity Read ↗

Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables.Semantic proximity Read ↗

Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.Semantic proximity Read ↗

Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.Semantic proximity Read ↗

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.Semantic proximity Read ↗

Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection.Semantic proximity Read ↗

Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.Semantic proximity Read ↗

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.Semantic proximity Read ↗

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.Semantic proximity Read ↗

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.Semantic proximity Read ↗

Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.